Targeting the FcRn: A Novel Approach to the Treatment of Pemphigus.

[1]  V. Werth,et al.  Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. , 2021, The Journal of investigative dermatology.

[2]  D. Patel,et al.  Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. , 2020, The Journal of allergy and clinical immunology.

[3]  H. de Haard,et al.  Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia , 2019, American journal of hematology.

[4]  L. Pearce,et al.  Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses , 2019, Science Advances.

[5]  P. van Damme,et al.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis , 2019, Neurology.

[6]  L. Marshall,et al.  Pemphigus , 2017, Nature Reviews Disease Primers.

[7]  T. Kuijpers,et al.  Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease. , 2013, The Journal of allergy and clinical immunology.

[8]  Yu-Huei Huang,et al.  Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. , 2012, The Journal of investigative dermatology.

[9]  R. Hubbard,et al.  Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study , 2008, BMJ : British Medical Journal.

[10]  J. Andersen,et al.  Dependence of antibody-mediated presentation of antigen on FcRn , 2008, Proceedings of the National Academy of Sciences.